RecruitingPhase 1NCT02254863
Rare condition
Schilder disease
14
studies recruiting now
as of 7 Sept 2026
80
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
19 Dec 2020
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT04675749
Quality of Life in Women With X-linked Adrenoleukodystrophy
RecruitingPhase 2NCT03630211
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RecruitingNCT03789721
Adrenoleukodystrophy National Registry Study
RecruitingNCT04528355
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 14 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Schilder disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Schilder disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
7 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Elivaldogene Tavalentivec
Phase 2/3Busulfan (Busilvex)
Phase 2/3Albumin Human (Albumin human component of abi-009)
Phase 2/3Cyclophosphamide (Cyclophosphamide)
Phase 2/3Leriglitazone
Phase 2Glyceryl Trierucate (Glyceryl trierucate component of lorenzo's oil)
Phase 2Glyceryl Trioleate
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).